Compare Mesoblast Limited (MESO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares UltraPro Short QQQ ETF — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while ProShares UltraPro Short QQQ ETF trades at $37.44. The key difference: Mesoblast Limited is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| MESO | SQQQ | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $92.95 |
52-Week Low | $12.88 | $36.31 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
SQQQ trades at $37.05, down 1.83% on the day, reflecting its inverse leveraged structure designed to move opposite the Nasdaq-100. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold conditions suggest potential for short-term bounces. Recent news highlights SQQQ's role as a tactical hedging tool rather than a long-term investment, with significant erosion risk due to daily reset mechanisms.
SQQQ serves as a high-risk tactical instrument for bearish Nasdaq-100 bets, with success dependent on precise market timing. The ETF faces structural decay from daily rebalancing, making it unsuitable for buy-and-hold strategies. Current market volatility and tech sector concerns create potential short-term opportunities, but long-term holders have historically suffered substantial losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
